The advent of PD-(L)1 inhibitors marks a monumental shift in the landscape of cancer treatment. These agents have redefined the therapeutic approach to several malignancies, offering hope where traditional therapies often fell short. PD-(L)1 inhibitors are a class of drugs that block the interaction between the programmed death-1 (PD-1) receptor on T cells and its ligand, PD-L1, on tumor cells. This interaction typically acts as a brake on the immune system, preventing T cells from attacking cancer cells. By inhibiting this pathway, PD-(L)1 inhibitors unleash the immune system to recognize and destroy cancer cells.
PD-1 inhibitors are expected to be the leading dru...
